Supplementary Table 1 and Supplemental Figure Legends from Cisplatin Alters Antitumor Immunity and Synergizes with PD-1/PD-L1 Inhibition in Head and Neck Squamous Cell Carcinoma
Year: 2023
Type: supplementary-materials
Abstract: Supplemental Table 1: HNSCC cell lines were treated with a range of cisplatin doses for 72 hours, and cell death was assessed using an annexin/7AAD flow cytometry assay in at least two independent experiments performed in triplicate for each cell line. Cell death curves were generated to estimate the doses required to kill 25% (LD25) or 50% (LD50) for each cell line.
Authors: Linda Tran, Clint T. Allen, Roy Xiao, Ellen Moore, Ruth Davis, So-Jin Park, Katie Spielbauer, Carter Van Waes, Nicole C. Schmitt
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362628848